Core Insights - The study demonstrates the potential of hypoimmune-modified islet cells to treat type 1 diabetes without the need for immunosuppression, showing sustained insulin production over a 14-month period [1][2][3] - Sana Biotechnology is advancing its SC451 therapy, which aims to provide a one-time treatment for type 1 diabetes, with plans to file an Investigational New Drug (IND) application and initiate a Phase 1 trial as early as this year [1][3][7] Study Results - 14-month follow-up data indicates that C-peptide levels, a biomarker for insulin production, remained stable and comparable to the initial six months of the study, with improvements noted in glycemic control [2][6] - The study found no safety issues, and the transplanted cells demonstrated long-term survival and function, evading immune detection [3][4][6] Technology and Methodology - Sana's hypoimmune platform (HIP) allows for the transplantation of allogeneic cells without immunosuppression, addressing both allogeneic and autoimmune rejection in type 1 diabetes [4][7] - The study involved the transplantation of UP421, derived from deceased donor islet cells, into patients, with a focus on safety and cell function [5][6] Future Directions - The company aims to enhance the scalability of its therapies, with SC451 being a key focus for providing durable blood glucose control without the need for exogenous insulin [3][7] - Collaboration with Uppsala University Hospital continues to be pivotal in advancing the research and development of hypoimmune-modified therapies [3][8]

Core Insights - The ongoing UP421 type 1 diabetes study shows that hypoimmune-modified pancreatic islet cells can be transplanted without immunosuppression, demonstrating safety and functionality one year post-transplant [1][2][8] - The company is advancing SC451, a hypoimmune-modified, stem cell-derived therapy aimed at achieving normal blood glucose levels without insulin or immunosuppression, with an IND filing expected this year [1][2][3] - Significant progress has been made in the development of SG293, a next-generation in vivo CAR T product candidate, with first-in-human data anticipated in blood cancers this year [1][2][3] Clinical Developments - The UP421 study, which is the first known example of allogeneic cell therapy for type 1 diabetes without immunosuppression, has shown positive results in safety, immune evasion, and islet cell function [2][3][8] - The study demonstrated that transplanted beta cells produce insulin, as indicated by C-peptide levels, and no safety issues were identified [8] - The company plans to initiate clinical trials for both SC451 and SG293 this year, aiming to provide significant clinical benefits for patients [2][3] Financial Highlights - The company raised gross proceeds of $133.7 million from common stock sales and equity financing in 2025, with a cash position of $138.4 million as of Q4 2025, expected to last into late 2026 [1][6][10] - Research and development expenses for 2025 were $132.0 million, a decrease from $215.7 million in 2024, attributed to portfolio prioritization and reduced operational costs [10][11] - The net loss for the year ended December 31, 2025, was $244.2 million, compared to $266.8 million in 2024, indicating a slight improvement in financial performance [11][28] Leadership and Corporate Strategy - The company strengthened its leadership team by appointing Brian Piper as Chief Financial Officer, bringing extensive experience in financial management within the biotechnology sector [9] - The focus remains on advancing two key platforms: hypoimmune technology for diabetes treatment and fusogen technology for CAR T cell therapies, aiming for scalable and effective treatments [2][4][5]

Core Thesis - Sana Biotechnology, Inc. (SANA) is positioned as a promising player in the treatment of type 1 diabetes (T1D) with its innovative gene-edited, hypoimmune cell therapy, SC451, which has shown unprecedented results in a patient remaining insulin-free for a year [2][5]. Company Overview - SANA focuses on utilizing engineered cells as medicines in the United States, specifically targeting T1D with its proprietary technology [2]. - The company is preparing to file its Investigational New Drug (IND) application for SC451, marking a transition from proof-of-concept to practical application [4]. Technological Advantage - SANA's use of CD47+ "invisibility" technology provides a significant edge over competitors like Vertex Pharmaceuticals (VRTX) and Sernova, which rely on conventional donor cells and chronic immunosuppression [3]. - The potential scalability of SANA's stem-cell-derived islets could allow for unlimited production, broadening eligibility for T1D patients and extending applications beyond diabetes [3]. Financial Position and Strategy - SANA has strategically redirected funds from a canceled factory plan to advance clinical trials and has raised enough capital to sustain operations into late 2026 [4]. - The current market capitalization of SANA is viewed as significantly undervaluing its technological lead, presenting a unique investment opportunity [5]. Key Catalysts - Important upcoming milestones include IND approval, initiation of Phase 1 trials, and continued validation of the hypoimmune stem-cell approach, which could enhance SANA's market position [5][6].

Group 1 - Sana Biotechnology Inc. appointed Brian Piper as Executive Vice President and Chief Financial Officer, bringing over 25 years of biopharmaceutical experience [1][3] - The leadership change occurs as the company approaches major clinical milestones, including initial clinical data for SC451 and SG293 expected in the next 12 to 18 months [2] - Financially, the company reported a strengthened balance sheet with approximately $133 million in equity financing, projecting a cash runway into late 2026 [3] Group 2 - Sana Biotechnology focuses on engineered cells as medicines, developing ex vivo and in vivo cell engineering platforms for various therapeutic areas [4]

Industry Overview - Genomics is the comprehensive study of genomes, which has intensified interest among pharmaceutical and biotechnology companies for deeper insights into disease biology and effective therapeutic strategies [1] - The global genomics market was valued at $34.23 billion in 2025 and is projected to grow from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% [8] - The global synthetic biology market was valued at $18.94 billion in 2025 and is expected to reach $69.18 billion by 2033, with a CAGR of 17.7% from 2026 to 2033 [8] Genomic Research and Applications - Insights from genomic research are increasingly used to evaluate patient responses to specific drugs, driving the development of targeted treatments and advancing personalized medicine [3] - The emergence of genome-editing technologies, particularly CRISPR/Cas9 systems, is enabling precise modifications to DNA, offering potential cures for diseases caused by genetic mutations [7] Key Companies - Illumina (ILMN) is a prominent player in genomic sequencing, recognized for its leadership in sequencing and array-based technologies [5] - Pacific Biosciences of California (PACB) focuses on advanced sequencing solutions and has seen its shares rise by 9.1% in the past year, currently holding a Zacks Rank 1 (Strong Buy) [10][12] - Caribou Biosciences (CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company, with shares surging 34.4% in the past year and a Zacks Rank 2 (Buy) [12][14] - Sana Biotechnology (SANA) is developing cell engineering platforms for diseases like type 1 diabetes and has seen its shares increase by 37.5% over the past year, also holding a Zacks Rank 2 [15][17]

Core Insights - Sana Biotechnology, Inc. has appointed Brian Piper as Executive Vice President and Chief Financial Officer, bringing over 25 years of biopharmaceutical financial and operational expertise [1][2] - The company anticipates generating initial clinical data for its therapies SC451 and SG293 within the next 12-18 months, which are aimed at treating type 1 diabetes and B-cell related diseases, respectively [2] - The leadership of Mr. Piper is expected to be critical in advancing the company's portfolio and optimizing long-term value creation [2][3] Company Overview - Sana Biotechnology focuses on creating engineered cells as medicines, with a vision to repair and control genes and replace missing or damaged cells [4] - The company operates in Seattle, WA, Cambridge, MA, and South San Francisco, CA [4]

Summary of Sana Biotechnology FY Conference Call Company Overview - **Company**: Sana Biotechnology (NasdaqGS:SANA) - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 14, 2026 - **Presenter**: Steve Harr, President and CEO Core Industry Focus - **Industry**: Biotechnology, specifically in cell therapy and gene editing - **Target Disease**: Type 1 diabetes and potential applications in blood cancers and autoimmune diseases Key Points and Arguments Goals and Progress - **Main Goals**: - Overcome allogeneic rejection in cell therapy to make it universally available - Develop effective delivery methods for genetic payloads to cells [2][3] - **Focus Area**: Type 1 diabetes, a significant unmet medical need with high demand for better treatment options [3][9] Achievements - **Cell Transplantation**: Successfully demonstrated the ability to transplant cells that evade the immune system [4] - **Master Cell Bank**: Established a master cell bank for consistent production of pancreatic beta cells [4][28] - **Regulatory Engagement**: Engaged with global regulators to align on future plans, including filing an Investigational New Drug (IND) application [4][29] Clinical Development - **Phase One Study**: Plans to file IND and begin Phase One study within the year, aiming for quick proof of concept regarding immune evasion and functional insulin production [4][30] - **Patient Outcomes**: A patient who received the therapy has shown no adverse events and continued insulin production for over a year [16][21] Scientific Insights - **Mechanism of Action**: - Knocking out MHC class I and II to prevent immune rejection, combined with overexpression of CD47 to evade both adaptive and innate immunity [13][14] - Evidence of survival and function of transplanted cells through C-peptide levels and PET MRI scans [17][21] Market Potential - **Unmet Need**: Curing type 1 diabetes could equate to curing both HIV and multiple sclerosis in the U.S., highlighting the vast market potential [9] - **Scalability**: The goal is to create a scalable therapy that can treat millions of patients, with a focus on manufacturing efficiency [28][58] Future Directions - **In Vivo CAR T Cells**: Development of a best-in-class in vivo CAR T platform, with plans to initiate trials in cancer and autoimmune diseases [43][60] - **Partnership Strategy**: Considering partnerships to accelerate development in competitive areas like B cell cancers and autoimmune diseases [60] Regulatory and Manufacturing Challenges - **Regulatory Complexity**: Navigating the complexities of novel immunology, gene editing, and stem cell biology with regulators [51] - **Manufacturing Scale**: Challenges in scaling production from Phase One to commercial levels, focusing on maintaining genomic stability and purity [45][47] Investment and Financial Outlook - **Investment Needs**: Significant investment required for manufacturing scale-up and clinical development, with ongoing financial commitments expected [56][58] Additional Important Insights - **Patient Population for Trials**: Initial trials will focus on adults with type 1 diabetes, with plans to expand to younger populations as data is gathered [52][53] - **Global Reach**: The Phase One study will not be limited to the U.S. but will include other geographies [54] This summary encapsulates the key points discussed during the conference call, highlighting Sana Biotechnology's strategic focus, achievements, and future plans in the biotechnology sector.

Corporate Presentation January 2026 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this presentation, including, among others, statements regarding the Company's strategy, expectations, cash runway and future financial condition, future operations, and prospects ...

Industry Overview - Genomics is a comprehensive study of genomes, which has gained significant interest from pharmaceutical and biotechnology companies for understanding diseases and developing therapies [2] - The distinction between genetics and genomics is crucial, with genomics focusing on the complete set of genes and their interactions within an organism [3] - Insights from genomic research are increasingly utilized to evaluate patient responses to drugs and support the development of targeted therapies, advancing personalized medicine [4] - The growth of genomics has also bolstered synthetic biology, which applies engineering principles to biology for various applications, including drug discovery and gene editing [5] - The rapid advancements in genomics are driven by significant reductions in the cost and time required for genome sequencing [6] Market Projections - The genomics market is projected to reach $80.17 billion by 2032 [9] - The global synthetic biology market was valued at $18.94 billion in 2025 and is expected to grow at a CAGR of 17.7% from 2026 to 2033 [9] Key Companies - **Pacific Biosciences of California (PACB)**: Specializes in advanced long-read sequencing systems for various applications, including healthcare and agriculture. The company has a Zacks Rank 2 (Buy) [12][14] - **Wave Life Sciences (WVE)**: A clinical-stage biotechnology company focusing on RNA medicines. The company reported positive interim data for its obesity treatment candidate WVE-007, which showed improvements in body composition [15][17] - **Sana Biotechnology (SANA)**: Developing cell engineering platforms for diseases like type 1 diabetes and B-cell cancers. The company has suspended its CAR T programs to focus on more promising candidates and has a Zacks Rank 3 [19][21]

Core Insights - The company is focused on innovative approaches in the field of in vivo CAR-T therapy, emphasizing its unique position in a competitive landscape [1] - The primary asset of interest is SC451, aimed at providing a functional cure for type 1 diabetes, a condition affecting approximately 9 million individuals [2] Company Overview - The company was founded on two main ideas: evading immune detection of cells and delivering specific payloads to targeted cells in vivo [2] - The development of SC451 is a significant focus, indicating the company's commitment to addressing unmet medical needs in diabetes treatment [2]